[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Andrew Caravello, DO [@andrewcaravello](/creator/twitter/andrewcaravello) on x 1072 followers Created: 2025-07-14 14:17:54 UTC $NWBO DCVax-L Gains First Ever Recognition in the Academic Oncology Framework for Glioblastoma 🧠💉📊 A July 2025 radiotherapy review authored by oncology experts from Spain marks a material shift in how #DCVax-L is positioned within the treatment discourse for glioblastoma. For the first time, a peer facing academic publication has included DCVax-L in a structured immunotherapy comparison table alongside checkpoint inhibitors, oncolytic viruses, vaccine platforms, and cytokine based therapies. The table presents phase III data with median overall survival of XXXX months in recurrent GBM (rGBM, without radiotherapy) and XXXX months in newly diagnosed GBM (nGBM, with radiotherapy and temozolomide). This is not a footnote or speculative mention. It is the first instance of DCVax-L being formally benchmarked against other immunotherapies in a comparative clinical framework designed by unaffiliated academic oncologists. The significance lies not in regulatory status, which DCVax-L has not yet achieved, but in structural recognition. DCVax-L is presented with trial phase identifiers, median survival outcomes, and mechanistic classification consistent with agents that have already entered clinical guidelines. Although marked “non standard,” this qualifier reflects absence of formal authorization rather than lack of clinical data. Until now, DCVax-L has largely been siloed in standalone publications or investor discussions. This publication marks its entry into the evaluative tools that guide peer level oncology decision making, research prioritization, and therapeutic benchmarking. That distinction sets a precedent for how future immunotherapies without approval may still be assessed based on performance. This recognition is also contextually significant. The review highlights the consistent failure of standard radiotherapy to prevent local recurrence, the molecular resistance mechanisms (EGFR, PTEN, CDKN2A/B), and the immunosuppressive effects of treatment induced lymphopenia. In that landscape, DCVax-L’s autologous dendritic cell strategy personalized to patient specific tumor lysate stands apart from fixed target agents. Its survival performance in both rGBM and nGBM compares favorably to many targeted and immune therapies already tested in phase II and III trials. The inclusion of DCVax-L in this matrix signals academic willingness to reconsider where evidence belongs, even in the absence of regulatory codification. Most importantly, this has never been done before. Prior academic reviews have not included DCVax-L in formal therapeutic tables or survival benchmarks. This is the first such instance where DCVax-L is structurally evaluated against contemporaneous therapies using phase specific metrics. It enters the analytical apparatus that defines clinical relevance not as an exception, but as a comparator. This shift opens the door to downstream effects including guideline level discourse, cooperative group protocol integration, and health technology assessment. It is not regulatory approval, but it is the academic equivalent of clearing the first gate. 🚀📘🏥 Thanks @sharpie510 you’re absolutely right. People should be freezing their tumor. #Glioblastoma #GBM #DCVaxL #Immunotherapy #CancerVaccine #Oncology #NeuroOncology #ASTRO2025 #ESTRO #Radiotherapy #CheckpointInhibitors #TumorTreatingFields #PersonalizedMedicine #MGMT #EGFR #PTEN #DendriticCells $NWBO $IBB $XBI $JNJ $MRK $REGN $BMY $PFE $AZN $GILD $AMGN $LLY $VRTX $VCYT $TCRT $CELU $INDP $ADPT $IOVA $BLUE $CRSP $EDIT $NTLA XXXXX engagements  **Related Topics** [marks](/topic/marks) [spain](/topic/spain) [$nwbo](/topic/$nwbo) [Post Link](https://x.com/andrewcaravello/status/1944763287830163757)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Andrew Caravello, DO @andrewcaravello on x 1072 followers
Created: 2025-07-14 14:17:54 UTC
$NWBO DCVax-L Gains First Ever Recognition in the Academic Oncology Framework for Glioblastoma 🧠💉📊
A July 2025 radiotherapy review authored by oncology experts from Spain marks a material shift in how #DCVax-L is positioned within the treatment discourse for glioblastoma. For the first time, a peer facing academic publication has included DCVax-L in a structured immunotherapy comparison table alongside checkpoint inhibitors, oncolytic viruses, vaccine platforms, and cytokine based therapies. The table presents phase III data with median overall survival of XXXX months in recurrent GBM (rGBM, without radiotherapy) and XXXX months in newly diagnosed GBM (nGBM, with radiotherapy and temozolomide). This is not a footnote or speculative mention. It is the first instance of DCVax-L being formally benchmarked against other immunotherapies in a comparative clinical framework designed by unaffiliated academic oncologists.
The significance lies not in regulatory status, which DCVax-L has not yet achieved, but in structural recognition. DCVax-L is presented with trial phase identifiers, median survival outcomes, and mechanistic classification consistent with agents that have already entered clinical guidelines. Although marked “non standard,” this qualifier reflects absence of formal authorization rather than lack of clinical data. Until now, DCVax-L has largely been siloed in standalone publications or investor discussions. This publication marks its entry into the evaluative tools that guide peer level oncology decision making, research prioritization, and therapeutic benchmarking. That distinction sets a precedent for how future immunotherapies without approval may still be assessed based on performance.
This recognition is also contextually significant. The review highlights the consistent failure of standard radiotherapy to prevent local recurrence, the molecular resistance mechanisms (EGFR, PTEN, CDKN2A/B), and the immunosuppressive effects of treatment induced lymphopenia. In that landscape, DCVax-L’s autologous dendritic cell strategy personalized to patient specific tumor lysate stands apart from fixed target agents. Its survival performance in both rGBM and nGBM compares favorably to many targeted and immune therapies already tested in phase II and III trials. The inclusion of DCVax-L in this matrix signals academic willingness to reconsider where evidence belongs, even in the absence of regulatory codification.
Most importantly, this has never been done before. Prior academic reviews have not included DCVax-L in formal therapeutic tables or survival benchmarks. This is the first such instance where DCVax-L is structurally evaluated against contemporaneous therapies using phase specific metrics. It enters the analytical apparatus that defines clinical relevance not as an exception, but as a comparator. This shift opens the door to downstream effects including guideline level discourse, cooperative group protocol integration, and health technology assessment. It is not regulatory approval, but it is the academic equivalent of clearing the first gate. 🚀📘🏥
Thanks @sharpie510 you’re absolutely right. People should be freezing their tumor.
#Glioblastoma #GBM #DCVaxL #Immunotherapy #CancerVaccine #Oncology #NeuroOncology #ASTRO2025 #ESTRO #Radiotherapy #CheckpointInhibitors #TumorTreatingFields #PersonalizedMedicine #MGMT #EGFR #PTEN #DendriticCells $NWBO $IBB $XBI $JNJ $MRK $REGN $BMY $PFE $AZN $GILD $AMGN $LLY $VRTX $VCYT $TCRT $CELU $INDP $ADPT $IOVA $BLUE $CRSP $EDIT $NTLA
XXXXX engagements
